A good time to review the previous floor at 60.xx that we have been tracking for almost a year in $GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials: On the Remdesivir (GS-5734) side,...
We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street...
GSK is showing a macro uptrend. Bearish divergence showing on the MACD and RSI. I have marked the previous divergence also, which preceded a sharp fall. We may be coming down to test the support line. The 2007-2009 dip is shown (38%)
I like what they do , has been in my #DRIP for many years , but lousy experience for the longs on #trade , maybe option folks ..easy just buy puts and never calls ,LOL
Price has tested 1380 numerous times which can be seen with the long wicks testing and rejecting this level. There is RSI Divergence also which shows weakness in the price, sell a break of the counter trend and target the lows. Alternatively set an alert just above 1380 if the price breaks and closes above this level it would be a strong buy signal.
Nice setup, down side is limited, it's in monthly range of 60-30, downside is limited, Buy bottom of the range, a potential breakout to the upside will go over 100...